<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043458</url>
  </required_header>
  <id_info>
    <org_study_id>M11-108</org_study_id>
    <nct_id>NCT01043458</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia</brief_title>
  <official_title>A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and
      eliminated by the body of stable schizophrenic volunteers receiving treatment with an
      atypical antipsychotic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ABT-126 levels in blood (plasma)</measure>
    <time_frame>Pre-dose to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests, vital signs and electrocardiogram (ECG)</measure>
    <time_frame>Pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-126 Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-126 High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for ABT-126</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-126</intervention_name>
    <description>ABT-126 Low Dose &amp; ABT-126 High Dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABT-126</intervention_name>
    <description>Matching Placebo for Arms 1 &amp; 2</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed informed consent;

          -  Current diagnosis of schizophrenia;

          -  Clinically stable on the same single second-generation (atypical) antipsychotic for
             the past 8 weeks;

          -  Meets study-specific criteria for Positive and Negative Syndrome Scale (PANSS);

          -  Females are not pregnant, not breast-feeding;

          -  Females are post-menopausal or surgically sterile or practicing birth control;

          -  Males are surgically sterile or agree to be sexually inactive or use barrier method of
             birth control

        Exclusion Criteria:

          -  Diagnosis of schizoaffective disorder;

          -  Diagnosis with mental retardation;

          -  Subject has a substance dependence disorder that has not been in sustained remission
             for at least 1 year;

          -  Acute psychosis hospitalization within past 6 months;

          -  Bipolar disorder, manic episode, dementia, obsessive-compulsive disorder, or
             drug-induced psychosis or current major depressive disorder;

          -  Current clozapine treatment;

          -  Suicidal ideation or behavior;

          -  BMI of 39 or greater;

          -  Relevant drug sensitivity or allergy;

          -  Positive hepatitis or HIV test result; positive urine screen for drugs of abuse or
             alcohol;

          -  Recent clinically significant illness/infection or surgery;

          -  Recent blood product transfusion, donation or loss of 5 mL/kg of blood;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 25423</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 24322</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hana Florian, MD / Associate Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

